THERIVA BIOLOGICS INC
(NYSE Mkt: TOVX)
Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-020 and SYN-004. SYN-020 is intended to prevent the antibiotic-mediated microbiome damage, C. difficile infections (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host disease (aGVHD) in allogeneic HCT recipients. SYN-004 is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.
0.257
+0.016
(+6.64%)
Range
0.242 - 0.260
(7.44%)
Open
0.246
Previous Close
0.241
Bid Price
-
Bid Volume
-
Ask Price
-
Ask Volume
-
Volume
225,173
Value
-
Remark
View All Events
Loading Chart...
Please login to view stock data and analysis